195 related articles for article (PubMed ID: 24923427)
41. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Martin LA; Davies GL; Weigel MT; Betambeau N; Hills MJ; Salter J; Walsh G; A'Hern R; Dowsett M
Breast Cancer Res Treat; 2010 Oct; 123(3):829-36. PubMed ID: 20697803
[TBL] [Abstract][Full Text] [Related]
42. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
Brueggemeier RW; Díaz-Cruz ES; Li PK; Sugimoto Y; Lin YC; Shapiro CL
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):129-36. PubMed ID: 15964185
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
44. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
[TBL] [Abstract][Full Text] [Related]
45. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Chu TH; Chan HH; Kuo HM; Liu LF; Hu TH; Sun CK; Kung ML; Lin SW; Wang EM; Ma YL; Cheng KH; Lai KH; Wen ZH; Hsu PI; Tai MH
Oncotarget; 2014 Mar; 5(6):1475-90. PubMed ID: 24721996
[TBL] [Abstract][Full Text] [Related]
46. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.
Gee J; Lee IL; Jendiroba D; Fischer SM; Grossman HB; Sabichi AL
Oncol Rep; 2006 Feb; 15(2):471-7. PubMed ID: 16391871
[TBL] [Abstract][Full Text] [Related]
47. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.
Dhawan D; Jeffreys AB; Zheng R; Stewart JC; Knapp DW
Mol Cancer Ther; 2008 Apr; 7(4):897-904. PubMed ID: 18413803
[TBL] [Abstract][Full Text] [Related]
48. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Lustberg MB; Povoski SP; Zhao W; Ziegler RM; Sugimoto Y; Ruppert AS; Lehman AM; Shiels DR; Mrozek E; Ramaswamy B; Layman RM; Brueggemeier RW; Shapiro CL
Clin Breast Cancer; 2011 Aug; 11(4):221-7. PubMed ID: 21729671
[TBL] [Abstract][Full Text] [Related]
50. Aromatase and COX in breast cancer: enzyme inhibitors and beyond.
Brueggemeier RW; Su B; Sugimoto Y; Díaz-Cruz ES; Davis DD
J Steroid Biochem Mol Biol; 2007; 106(1-5):16-23. PubMed ID: 17616393
[TBL] [Abstract][Full Text] [Related]
51. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.
Krysan K; Kusko R; Grogan T; O'Hearn J; Reckamp KL; Walser TC; Garon EB; Lenburg ME; Sharma S; Spira AE; Elashoff D; Dubinett SM
Mol Cancer Res; 2014 May; 12(5):765-74. PubMed ID: 24469837
[TBL] [Abstract][Full Text] [Related]
52. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D
Lundqvist J; Kirkegaard T; Laenkholm AV; Duun-Henriksen AK; Bak M; Feldman D; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2018 Mar; 177():171-178. PubMed ID: 28610873
[TBL] [Abstract][Full Text] [Related]
53. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis.
Gallouet AS; Travert M; Bresson-Bepoldin L; Guilloton F; Pangault C; Caulet-Maugendre S; Lamy T; Tarte K; Guillaudeux T
Clin Cancer Res; 2014 May; 20(10):2663-73. PubMed ID: 24637636
[TBL] [Abstract][Full Text] [Related]
54. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Saito T; Tamura D; Asano R
Oncol Rep; 2014 Apr; 31(4):1637-44. PubMed ID: 24503782
[TBL] [Abstract][Full Text] [Related]
55. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Basu GD; Pathangey LB; Tinder TL; Lagioia M; Gendler SJ; Mukherjee P
Mol Cancer Res; 2004 Nov; 2(11):632-42. PubMed ID: 15561779
[TBL] [Abstract][Full Text] [Related]
56. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Mustafa A; Kruger WD
Clin Cancer Res; 2008 Aug; 14(15):4935-42. PubMed ID: 18676768
[TBL] [Abstract][Full Text] [Related]
57. Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells.
Yu X; Zhang X; Dhakal IB; Beggs M; Kadlubar S; Luo D
BMC Cancer; 2012 Jan; 12():29. PubMed ID: 22260523
[TBL] [Abstract][Full Text] [Related]
58. Estrogen metabolites and breast cancer.
Santen RJ; Yue W; Wang JP
Steroids; 2015 Jul; 99(Pt A):61-6. PubMed ID: 25168343
[TBL] [Abstract][Full Text] [Related]
59. Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.
Xia W; Zhao T; Lv J; Xu S; Shi J; Wang S; Han X; Sun Y
J Cell Biochem; 2009 Sep; 108(1):181-94. PubMed ID: 19562670
[TBL] [Abstract][Full Text] [Related]
60. Different cell cycle modulation by celecoxib at different concentrations.
Kim YM; Pyo H
Cancer Biother Radiopharm; 2013 Mar; 28(2):138-45. PubMed ID: 23268707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
